Oric Pharmaceuticals, Inc. ORIC Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Oric Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oric Pharmaceuticals, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oric Pharmaceuticals, Inc.'s additional paid-in capital?
- Oric Pharmaceuticals, Inc. (ORIC) reported additional paid-in capital of $1.14B in Q1 2026.
- How has Oric Pharmaceuticals, Inc.'s additional paid-in capital changed year-over-year?
- Oric Pharmaceuticals, Inc.'s additional paid-in capital increased by 40.8% year-over-year, from $812.32M to $1.14B.
- What is the long-term trend for Oric Pharmaceuticals, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Oric Pharmaceuticals, Inc.'s additional paid-in capital has grown at a 18.7% compound annual growth rate (CAGR), from $456.2M to $1.08B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.